Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Visit
ASCO 2022
;
🎥@evaciruelos of @hospital12Oct discusses Phase II ACROSS-TROP2 study exploring predictive biomarkers and resistance mechanisms in HR+/HER2- advanced #breastcancer. Exciting prospects at #ESMOBreast2024:
➡️⬅️
@myESMO
ACROSS-TROP2: identifying predictive biomarkers of SG in HR+/HER2- breast cancer
Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, gives an overview of the rationale and trial design ...
ow.ly
#ESMOBreast24 | Always a pleasure to speak to @Icro_Meattini, Orit Kaidar-Person and Philip Poortmans on radiation updates in #breastcancer, including RT in the setting of pCR.
Hear their insights and more at http://VJOncology.com🖱️
@myESMO @OncoAlert #bcsm
#ESMOBreast24 | We spoke to Sung-Bae Kim, who gave us updated OS findings on Destiny-Breast02, which highlights the benefits of T-DXd in HER2+ mBC
If you missed the session, visit http://VJOncology.com to see his talk and more in #breastcancer!
@myESMO #bcsm @Oncoalert
Join us for our Post-ASCO 2024 Highlights 📣
Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦
Agendas available soon 📝
REGISTER 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/
#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1
#ESMOBreast24 | We had the opportunity to catch up with @DrSGraff, who spoke on:
⭐1L CDK4/6 inhibitor trial data in HR+/HER2− #breastcancer
⭐Sequencing CDK4/6 inhibitors in the clinic
⭐The benefits of multidisciplinary care
@myESMO #bcsm @Oncoalert
ASCO 2022
🎥@evaciruelos of @hospital12Oct discusses Phase II ACROSS-TROP2 study exploring predictive biomarkers and resistance mechanisms in HR+/HER2- advanced #breastcancer. Exciting prospects at #ESMOBreast2024:
➡️⬅️
@myESMO
ACROSS-TROP2: identifying predictive biomarkers of SG in HR+/HER2- breast cancer
Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, gives an overview of the rationale and trial design ...
ow.ly
#ESMOBreast24 | Always a pleasure to speak to @Icro_Meattini, Orit Kaidar-Person and Philip Poortmans on radiation updates in #breastcancer, including RT in the setting of pCR.
Hear their insights and more at http://VJOncology.com🖱️
@myESMO @OncoAlert #bcsm
#ESMOBreast24 | We spoke to Sung-Bae Kim, who gave us updated OS findings on Destiny-Breast02, which highlights the benefits of T-DXd in HER2+ mBC
If you missed the session, visit http://VJOncology.com to see his talk and more in #breastcancer!
@myESMO #bcsm @Oncoalert
Join us for our Post-ASCO 2024 Highlights 📣
Featuring presentations & panel discussions on selected abstracts from #ASCO 2024 🔦
Agendas available soon 📝
REGISTER 👉 https://www.vjoncology.com/feature/post-asco-2024-highlights/
#ASCO24 @DrSanjayPopat @tompowles1 @stolaney1 @LizzySmyth1
#ESMOBreast24 | We had the opportunity to catch up with @DrSGraff, who spoke on:
⭐1L CDK4/6 inhibitor trial data in HR+/HER2− #breastcancer
⭐Sequencing CDK4/6 inhibitors in the clinic
⭐The benefits of multidisciplinary care
@myESMO #bcsm @Oncoalert
